{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T08:43:35Z","timestamp":1789807415848,"version":"4.0.1"},"reference-count":39,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"NHS Tayside Research Endowments"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Context<\/jats:title><jats:p>Primary hyperparathyroidism (PHPT) is associated with increased risk of morbidity and death, and vitamin D levels are a potentially confounding variable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of this study was to assess morbidity and mortality associated with primary hyperparathyroidism (PHPT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this population-based retrospective matched cohort study, data linkage of biochemistry, hospital admissions, prescribing, imaging, pathology, and deaths was used to identify patients across the region of Tayside, Scotland, who had PHPT from 1997 to 2019. Cox proportional hazards models and hazards ratios (HR) were used to explore the relationship between exposure to PHPT and several clinical outcomes. Comparisons were made with an age- and gender-matched cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In 11 616 people with PHPT (66.8% female), with a mean follow-up period of 8.8 years, there was an adjusted HR of death of 2.05 (95% CI, 1.97-2.13) for those exposed to PHPT. There was also an increased risk of cardiovascular disease (HR = 1.34; 95% CI, 1.24-1.45), cerebrovascular disease (HR = 1.29; 95% CI, 1.15-1.45), diabetes (HR = 1.39; 95% CI, 1.26-1.54), renal stones (HR = 3.02; 95% CI, 2.19-4.17) and osteoporosis (HR = 1.31; 95% CI, 1.16-1.49). Following adjustment for serum vitamin D concentrations (n = 2748), increased risks for death, diabetes, renal stones, and osteoporosis persisted, but not for cardiovascular or cerebrovascular disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In a large population-based study, PHPT was associated with death, diabetes, renal stones, and osteoporosis, independent of serum vitamin D concentration.<\/jats:p><\/jats:sec>","DOI":"10.1210\/clinem\/dgad103","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T08:48:58Z","timestamp":1677055738000},"page":"e842-e849","source":"Crossref","is-referenced-by-count":12,"title":["Morbidity Associated With Primary Hyperparathyroidism\u2014A Population-based Study With a Subanalysis on Vitamin D"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8424-5301","authenticated-orcid":false,"given":"Enrique","family":"Soto-Pedre","sequence":"first","affiliation":[{"name":"Division of Population Health & Genomics, School of Medicine, Ninewells Hospital & Medical School, University of Dundee , Dundee DD1 9SY , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeun Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Ninewells Hospital & Medical School, University of Dundee , Dundee DD1 9SY , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimena","family":"Soto-Hernaez","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Bristol , Bristol BS8 1QU , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J","family":"Newey","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Ninewells Hospital & Medical School, University of Dundee , Dundee DD1 9SY , UK"},{"name":"Division of Molecular & Clinical Medicine, School of Medicine, Ninewells Hospital & Medical School, University of Dundee , Dundee DD1 9SY , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham P","family":"Leese","sequence":"additional","affiliation":[{"name":"Division of Population Health & Genomics, School of Medicine, Ninewells Hospital & Medical School, University of Dundee , Dundee DD1 9SY , UK"},{"name":"Department of Endocrinology and Diabetes, Ninewells Hospital & Medical School, University of Dundee , Dundee DD1 9SY , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"issue":"3","key":"2023081819554662800_dgad103-B1","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1210\/jc.2012-4022","article-title":"Incidence and prevalence of primary hyperparathyroidism in a racially mixed population","volume":"98","author":"Yeh","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023081819554662800_dgad103-B2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2265.2008.03520.x","article-title":"Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK","volume":"71","author":"Yu","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2023081819554662800_dgad103-B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2014.12.003","article-title":"Secular trends in the incidence of primary hyperparathyroidism over five decades (1965-2010)","volume":"73","author":"Griebeler","year":"2015","journal-title":"Bone"},{"issue":"10","key":"2023081819554662800_dgad103-B4","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1210\/jc.2014-1413","article-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop","volume":"99","author":"Bilezikian","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023081819554662800_dgad103-B5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2265.2010.03958.x","article-title":"A record linkage study of outcomes in patients with mild primary hyperparathyroidism: the Parathyroid Epidemiology and Audit Research Study (PEARS)","volume":"75","author":"Yu","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"2023081819554662800_dgad103-B6","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1210\/jc.2014-1415","article-title":"Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop","volume":"99","author":"Silverberg","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2023081819554662800_dgad103-B7","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/jch.13064","article-title":"Plasma parathyroid hormone and cardiovascular disease in treatment-naive patients with primary hyperparathyroidism: the EPATH trial","volume":"19","author":"Wetzel","year":"2017","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"2","key":"2023081819554662800_dgad103-B8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/07435801003724503","article-title":"Insulin resistance before and after parathyroidectomy in patients with primary hyperparathyroidism\u2013a pilot study","volume":"35","author":"Rudman","year":"2010","journal-title":"Endocr Res"},{"issue":"1","key":"2023081819554662800_dgad103-B9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12020-020-02519-7","article-title":"The influence of parathyroidectomy on cardiometabolic risk factors in patients with primary hyperparathyroidism: a systematic review and meta-analysis","volume":"72","author":"Yavari","year":"2021","journal-title":"Endocrine"},{"issue":"1","key":"2023081819554662800_dgad103-B10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-016-3716-2","article-title":"Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus","volume":"28","author":"Khan","year":"2017","journal-title":"Osteoporos Int"},{"key":"2023081819554662800_dgad103-B11"},{"issue":"11","key":"2023081819554662800_dgad103-B12","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1210\/jc.2018-01225","article-title":"Primary hyperparathyroidism","volume":"103","author":"Bilezikian","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2023081819554662800_dgad103-B13","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/jbmr.4670","article-title":"The Fifth International Workshop on the evaluation and management of primary hyperparathyroidism","volume":"37","author":"Bilezikiam","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2023081819554662800_dgad103-B14","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11154-021-09694-6","article-title":"The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies","volume":"23","author":"Chandran","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"issue":"6","key":"2023081819554662800_dgad103-B15","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/qjmed\/hcq261","article-title":"The natural history of treated and untreated primary hyperparathyroidism: the parathyroid epidemiology and audit research study","volume":"104","author":"Yu","year":"2011","journal-title":"QJM"},{"issue":"4","key":"2023081819554662800_dgad103-B16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-8587(13)70083-4","article-title":"Subclinical and asymptomatic parathyroid disease: implications of emerging data","volume":"1","author":"Macfarlane DP","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"2023081819554662800_dgad103-B17","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.3390\/nu13103603","article-title":"Vitamin D and cardiovascular disease: current evidence and future perspectives","volume":"13","author":"Cosentino","year":"2021","journal-title":"Nutrients"},{"issue":"5","key":"2023081819554662800_dgad103-B18","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1016\/j.clnu.2020.12.025","article-title":"Vitamin D and cardiovascular health","volume":"40","author":"de la Gu\u00eda-Galipienso","year":"2021","journal-title":"Clin Nutr"},{"issue":"4","key":"2023081819554662800_dgad103-B19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/CRD.0000000000000138","article-title":"Vitamin D deficiency and supplementation in cardiovascular disorders","volume":"25","author":"Mihos","year":"2017","journal-title":"Cardiol Rev"},{"issue":"2","key":"2023081819554662800_dgad103-B20","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00774-017-0833-8","article-title":"Primary hyperparathyroidism: insights from the Indian PHPT registry","volume":"36","author":"Bhadada","year":"2018","journal-title":"J Bone Miner Metab"},{"key":"2023081819554662800_dgad103-B21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bone.2014.12.067","article-title":"Mortality associated with primary hyperparathyroidism","volume":"74","author":"Clifton-Bligh","year":"2015","journal-title":"Bone"},{"issue":"6","key":"2023081819554662800_dgad103-B22","doi-asserted-by":"crossref","first-page":"e2215396","DOI":"10.1001\/jamanetworkopen.2022.15396","article-title":"Analysis of comorbidities, clinical outcomes, and parathyroidectomy in adults with primary hyperparathyroidism","volume":"15","author":"Axelsson","year":"2022;","journal-title":"JAMA Netw Open"},{"key":"2023081819554662800_dgad103-B23","author":"Soto"},{"key":"2023081819554662800_dgad103-B24"},{"key":"2023081819554662800_dgad103-B25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/978-1-4615-2009-2_5","article-title":"Goodness-of-fit and diagnostics for proportional hazards regression models","volume":"75","author":"Grambsch","year":"1995","journal-title":"Cancer Treat Res"},{"issue":"3","key":"2023081819554662800_dgad103-B26","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-19-0316","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: Unmet therapeutic, educational and scientific needs in parathyroid disorders","volume":"181","author":"Bollerslev","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"2023081819554662800_dgad103-B27","author":"Public Health England","year":"2020."},{"issue":"1","key":"2023081819554662800_dgad103-B28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2265.2009.03766.x","article-title":"Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS)","volume":"73","author":"Yu","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"2023081819554662800_dgad103-B29","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1210\/jc.2018-02483","article-title":"Predictors of nephrolithiasis, osteoporosis, and mortality in primary hyperparathyroidism","volume":"104","author":"Reid","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2023081819554662800_dgad103-B30","doi-asserted-by":"crossref","first-page":"116099","DOI":"10.1016\/j.bone.2021.116099","article-title":"Survival in primary hyperparathyroidism over five decades (1965-2010) a population-based retrospective study","volume":"152","author":"Wermers","year":"2021","journal-title":"Bone"},{"issue":"6","key":"2023081819554662800_dgad103-B31","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1210\/clinem\/dgab157","article-title":"Meta-analysis on the effect of mild primary hyperparathyroidism and parathyroidectomy upon arterial stiffness","volume":"106","author":"Bernardi","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2023081819554662800_dgad103-B32","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1210\/jc.2009-1086","article-title":"Carotid vascular abnormalities in primary hyperparathyroidism","volume":"94","author":"Walker","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023081819554662800_dgad103-B33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12872-019-1093-4","article-title":"Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism","volume":"19","author":"Beysel","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"issue":"7","key":"2023081819554662800_dgad103-B34","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1210\/jc.2008-2742","article-title":"Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism","volume":"94","author":"Bollerslev","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2023081819554662800_dgad103-B35","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1530\/EC-18-0259","article-title":"The effect of surgery on fat mass, lipid and glucose metabolism in mild primary hyperparathyroidism","volume":"7","author":"Godang","year":"2018","journal-title":"Endocr Connect"},{"issue":"1","key":"2023081819554662800_dgad103-B36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1677\/erc.1.01261","article-title":"The association between primary hyperparathyroidism and malignancy: nationwide cohort analysis on cancer incidence after parathyroidectomy","volume":"14","author":"Nilsson","year":"2007","journal-title":"Endocr Relat Cancer"},{"key":"2023081819554662800_dgad103-B37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejim.2017.06.001","article-title":"Occurrence of malignant neoplasia in patients with primary hyperparathyroidism","volume":"43","author":"Palmieri","year":"2017","journal-title":"Eur J Intern Med"},{"key":"2023081819554662800_dgad103-B38","doi-asserted-by":"crossref","DOI":"10.1177\/11795514211059494","article-title":"Frequency of parathyroid hormone assessment in the evaluation of hypercalcemia. A comparison between patients with and without a history of malignancy in a 20-year dataset of 20,954 patients","volume":"14","author":"Sheehan","year":"2021","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"issue":"2","key":"2023081819554662800_dgad103-B39","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3390\/nu14020303","article-title":"Critical appraisal of large vitamin D randomized controlled trials","volume":"14","author":"Pilz","year":"2022","journal-title":"Nutrients"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad103\/49516503\/dgad103.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/9\/e842\/51171930\/dgad103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/9\/e842\/51171930\/dgad103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T11:23:55Z","timestamp":1701948235000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/9\/e842\/7050764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,2,22]]},"published-print":{"date-parts":[[2023,8,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad103","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,2,22]]}}}